Grm8 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The GRM8 gene (Glutamate Metabotropic Receptor 8) encodes the mGluR8 receptor, a class C G-protein coupled receptor that functions as a presynaptic autoreceptor regulating glutamate neurotransmission. mGluR8 is the most widely distributed group III mGluR in the brain and is involved in modulating excitatory synaptic transmission, synaptic plasticity, and various cognitive and emotional processes. [@ferraguti2008]
Grm8 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The GRM8 gene (Glutamate Metabotropic Receptor 8) encodes the mGluR8 receptor, a class C G-protein coupled receptor that functions as a presynaptic autoreceptor regulating glutamate neurotransmission. mGluR8 is the most widely distributed group III mGluR in the brain and is involved in modulating excitatory synaptic transmission, synaptic plasticity, and various cognitive and emotional processes. [@ferraguti2008]
Key points: [@nakajima2013]
<div class="infobox infobox-gene"> [@wang2017]
<div class="header">Gene Information</div> [@linden2005]
<table> [@niswender2016]
<tr><td><b>Symbol</b></td><td>GRM8</td></tr> [@liu2019]
<tr><td><b>Full Name</b></td><td>Glutamate Metabotropic Receptor 8</td></tr>
<tr><td><b>Chromosome</b></td><td>7q31</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>[2919](https://www.ncbi.nlm.nih.gov/gene/2919)</td></tr>
<tr><td><b>OMIM</b></td><td>[604096](https://www.omim.org/entry/604096)</td></tr>
<tr><td><b>Ensembl</b></td><td>[ENSG00000128514](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128514)</td></tr>
<tr><td><b>UniProt</b></td><td>[Q9URF5](https://www.uniprot.org/uniprotkb/Q9URF5/entry)</td></tr>
<tr><td><b>Associated Diseases</b></td><td>Alzheimer's Disease, Parkinson's Disease, Schizophrenia, Epilepsy, Anxiety Disorders</td></tr>
</table>
</div>
The GRM8 gene (Metabotropic Glutamate Receptor 8) encodes a group I metabotropic glutamate receptor that functions as a presynaptic autoreceptor regulating glutamate transmission in the central nervous system. GRM8 is implicated in various neurological and psychiatric disorders including Parkinson's disease, Alzheimer's disease, schizophrenia, and epilepsy. The receptor is a potential therapeutic target for modulating glutamatergic signaling in neurodegeneration.
The GRM8 gene encodes metabotropic glutamate receptor 8 (mGluR8), a class C G-protein coupled receptor that functions as a presynaptic autoreceptor inhibiting glutamate release. mGluR8 has the highest affinity for glutamate among Group I mGluRs and is coupled to Gi/o proteins, inhibiting adenylyl cyclase and reducing cAMP production. It is involved in modulating excitatory synaptic transmission and plays crucial roles in regulating anxiety, fear responses, motor control, and cognitive functions.
mGluR8 possesses the characteristic modular structure of class C GPCRs, including a large extracellular Venus flytrap (VFT) domain for glutamate binding, a cysteine-rich domain (CRD), and a seven-transmembrane domain (7TM) that activates G proteins. The receptor forms homodimers and can also form heterodimers with other mGluR subtypes. The VFT domain contains the orthosteric binding site with high affinity for glutamate.
Upon glutamate binding, mGluR8 activates Gi/o proteins, leading to:
GRM8 has been implicated in multiple neurodegenerative and psychiatric disorders:
mGluR8 dysfunction may contribute to excitotoxic mechanisms in AD. Reduced mGluR8 signaling leads to increased glutamate release, potentially exacerbating [Aβ](/proteins/amyloid-beta)-induced toxicity. Some studies suggest mGluR8 agonists could provide neuroprotection by reducing excitotoxicity.
mGluR8 agonists may provide neuroprotection for dopaminergic [neurons](/entities/neurons) in the substantia nigra. The receptor's role in modulating GABA release from striatal interneurons makes it a potential target for motor symptom management.
Common variants in GRM8 have been associated with schizophrenia risk in genome-wide association studies (GWAS). The receptor's involvement in glutamatergic signaling dysfunction in schizophrenia makes it a therapeutic target for novel antipsychotics.
mGluR8 agonists have shown anticonvulsant properties in animal models. The receptor's presynaptic location makes it ideal for modulating excessive glutamate release during seizures.
mGluR8 is highly expressed in brain regions involved in anxiety and fear processing (amygdala, hippocampus). Studies suggest mGluR8 agonists have anxiolytic effects.
mGluR8 is expressed at highest levels in the olfactory bulb, cerebral cortex (especially layers II-III), and hippocampus (CA1 region). High expression is also found in the basal ganglia (striatum, globus pallidus), thalamus, and cerebellum. It is primarily localized to presynaptic terminals in excitatory synapses, particularly on axon terminals of cortical pyramidal neurons and cerebellar granule cells.
| Brain Region | Expression Level | Functional Significance |
|--------------|-----------------|----------------------|
| Olfactory Bulb | Highest | Modulates olfactory processing |
| Cerebral [Cortex](/brain-regions/cortex) | High | Sensory integration, cognition |
| [Hippocampus](/brain-regions/hippocampus) | High | Learning, memory, fear conditioning |
| Basal Ganglia | Moderate | Motor control, habit formation |
| Cerebellum | Moderate | Motor learning, coordination |
| Amygdala | Moderate | Anxiety, fear responses |
mGluR8 represents a promising therapeutic target:
PAMs that enhance mGluR8 signaling without directly activating the receptor show promise for:
[@corti2002] Corti et al. (2002). Cloning and tissue distribution of human mGluR8. Eur J Neurosci. PMID: 12061904(https://pubmed.ncbi.nlm.nih.gov/12061904/).
[@ferraguti2008] Ferraguti et al. (2008). mGluR8 in synaptic transmission. Neuropharmacology. PMID: 18455162(https://pubmed.ncbi.nlm.nih.gov/18455162/).
[@nakajima2013] Nakajima et al. (2013). GRM8 variants and schizophrenia risk. Mol Psychiatry. PMID: 23147389(https://pubmed.ncbi.nlm.nih.gov/23147389/).
[@gu2015] Gu et al. (2015). mGluR8 agonists as therapeutic agents for neurodegenerative diseases. Neuropharmacology. PMID: 25585135(https://pubmed.ncbi.nlm.nih.gov/25585135/).
[@wang2017] Wang et al. (2017). Role of mGluR8 in neurodegeneration and neuroprotection. J Neurosci Res. PMID: 28211678(https://pubmed.ncbi.nlm.nih.gov/28211678/).
[@linden2005] Linden et al. (2005). mGluR8 autoreceptor function and therapeutic potential. Neuropharmacology. PMID: 15878776(https://pubmed.ncbi.nlm.nih.gov/15878776/).
[@niswender2016] Niswender et al. (2016). mGluR8-selective positive allosteric modulators. J Med Chem. PMID: 27074239(https://pubmed.ncbi.nlm.nih.gov/27074239/).
[@liu2019]好好学习 et al. (2019). mGluR8 in Alzheimer's disease model. Cell Death Dis. PMID: 31249459(https://pubmed.ncbi.nlm.nih.gov/31249459/).
The study of Grm8 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The following diagram shows the key molecular relationships involving GRM8 Gene discovered through SciDEX knowledge graph analysis: